₹6.81
+₹0.13 (+1.95%)
Closed · As of 26 Aug 3:30 pm
Mkt Cap
₹56 Cr
P/E
-0.32
ROE
83.81%
ROCE
-27.87%
About Vivimed Labs Ltd
Vivimed Labs is engaged in the manufacture of Active Pharmaceutical ingredients (API’s), Intermediates and Nutraceutical ingredients with predominance in exports. In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management.
Founded
1988
CEO
V Manohar Rao
Employees
586
HQ
Hyderabad, India
About Vivimed Labs Ltd
Vivimed Labs is engaged in the manufacture of Active Pharmaceutical ingredients (API’s), Intermediates and Nutraceutical ingredients with predominance in exports. In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management.
Founded:1988
CEO:V Manohar Rao
Employees:586
HQ:Hyderabad, India
Finished Products
1Sales
₹240.40CrRaw Materials
1Raw Materials consumed
₹145.51CrPrice Performance & Market EventsPrice Performance
Loading chart data…
Key Metrics
Trading & valuation snapshot
52W High
₹29
52W Low
₹5
Volume50.92K
Avg VolumeN/A
BetaN/A
Dividend Yield0.00%
Key Financial Ratios
Profitability, leverage & efficiency at a glance
P/E Ratio
-0.32x
Valuation
P/B Ratio
N/A
Valuation
EPS
₹-21.28
Valuation
Dividend Yield
0.00%
Valuation
ROE
83.81%
Profitability
ROCE
-27.87%
Profitability
Revenue by Segment
Contribution & growth by business line
Pharma
-18.8%100.0%
₹116.27 Cr
Geographical Revenue Split
Domestic vs international exposure
Domestic
0.0%
International
0.0%
No geographic split data available
Strategic Relations
Collaborations, joint ventures & subsidiaries
No collaborations data available.
Forensic Metrics
Financial health & earnings-quality indicators
Revenue Quality
N/A
Days Sales Outstanding
Leverage
-1.89x
Debt-to-Equity
Earnings Quality
N/A
Cash Conversion Ratio
Efficiency
N/A
Asset Turnover
Earnings Quality
N/A
Accruals Ratio
Profitability
N/A
Gross Margin
Growth
-14.7%
Sales Growth
These metrics are derived from available financial disclosures and market data. Use them together with company filings and qualitative analysis before making decisions.